Online inquiry

IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8994MR)

This product GTTS-WQ8994MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8994MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10139MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ2130MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ13737MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ13073MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ1856MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ9212MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ8991MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ8404MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW